Journal
ACS INFECTIOUS DISEASES
Volume 1, Issue 5, Pages 186-197Publisher
AMER CHEMICAL SOC
DOI: 10.1021/id5000426
Keywords
Ebola virus; viral hemorrhagic fever; innate immunity; adaptive immunity; immunoevasion; antivirals; Ebola vaccines; Ebola therapeutics
Categories
Funding
- NIAID NIH HHS [U19 AI109945] Funding Source: Medline
Ask authors/readers for more resources
The filoviruses, Ebola virus (EBOV) and Marburg virus (MARV), are among the deadliest viruses that cause disease in humans, with reported case fatality rates of up to 90% in some outbreaks. The high virulence of EBOV and MARV is largely attributed to the ability of these viruses to interfere with the host immune response. Currently, there are no approved vaccines or postexposure therapeutics, and treatment options for patients infected with EBOV are limited to supportive care. In this review, we discuss mechanisms of EBOV pathogenesis and its ability to subvert host immunity as well as several vaccines and therapeutics with respect to their evaluation in small animal models, nonhuman primates, and human clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
